You are here: Industry Insights > MCL

News List

Clinical Study Result of Orelabrutinib in Patients with R/R MCL Published by Blood Advances PharmaSources
May 04, 2023
Blood Advances recently published the clinical study study result of BTK inhibitor orelabrutinib in Relapsed or Refractory Mantle Cell Lymphoma patients.
InnoCare Announces Inclusion of Orelabrutinib in China National Reimbursement Drug List prnasia
December 03, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today that its BTK inhibitor orelabrutinib has been included in the updated National Reimbursement Drug List (NRDL)...
Tecartus wins NICE recommendation for mantle cell lymphoma pharmatimes
January 20, 2021
The UK’s National Centre for Health and Care Excellence (NICE) has recommended Kite’s CAR-T therapy Tecartus (autologous anti-CD19 transduced CD3+ cells) for the treatment of certain adult patients with relapsed or refractory mantle cell lymphoma ...
Gilead's CAR T therapy Tecartus authorised in EU for MCL pharmatimes
December 18, 2020
Gilead’s Kite division has announced that its chimericantigen receptor (CAR) T cell therapy Tecartus has received conditional marketing authorisation for the treatment of relapsed or refractory mantle cell lymphoma (MCL).
Calquence shows long-term efficacy and tolerability in MCL pharmatimes
December 08, 2020
Patients with relapsed or refractory mantle cell lymphoma (MCL) treated with AstraZeneca's Calquence (acalabrutinib) remained progression free for a median of 22 months, with median overall survival not yet reached at three years of follow-up ...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma americanpharmaceuticalreview
August 03, 2020
The U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (TECARTUS, Kite, a Gilead Company).
Calquence Recommended for CHMP Approval for Chronic Lymphocytic Leukemia americanpharmaceuticalreview
July 31, 2020
AstraZeneca’s Calquence (acalabrutinib) has been recommended for marketing authorization in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukemia (CLL), the most common type of leukemia in adults.
FDA approves Tecartus, cell-based gene therapy to treat relapsed or refractory MCL in adults expresspharma
July 27, 2020
It also received ‘Orphan Drug’ designation, which provides incentives to assist and encourage the development of drugs for rare diseases.
ADC Therapeutics begins phase 2 portion of LOTIS 3 trial of Lonca, ibrutinibhave combo pharmaceutical-business-review
July 22, 2020
ADC Therapeutics announced that the first patient has been dosed in the pivotal Phase 2 portion of LOTIS 3, a Phase 1/2 clinical trial evaluating loncastuximab tesirine (Lonca, formerly ADCT-402) in combination with ibrutinib in patients with relapsed ...
Oncternal gets FDA orphan drug designations for cirmtuzumab to treat MCL and CLL pharmaceutical-business-review
July 06, 2020
Oncternal Therapeutics announced that the United States Food and Drug Administration (FDA) has granted the company orphan drug designations of cirmtuzumab for treatment of mantle cell lymphoma (MCL) and for treatment of chronic lymphocytic leukaemia ...

Previous page 1 2 Next page